srch

XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of …

07.04.2016 · XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice. Trial registration number

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS) ... Brief Summary: This is an international observational study in patients with ...

Introduction

Study design. A large, prospective, observational, single-arm, non-interventional study to evaluate the safety and efficacy of Xarelto® in the real world1 ...

Conclusion: XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice. Trial registration number: Clinicaltrials.gov: NCT01606995.

The prospective, observational XANTUS study demonstrated low rates of stroke and major bleeding in real-world rivaroxaban-treated patients with non-valvular ...

Conclusion: XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice. Trial registration number: Clinicaltrials.gov: NCT01606995.

01.12.2018 · XANTUS-EL (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Eastern Europe, the Middle East and Africa [EEMEA] and Latin America) was the first real-world, prospective, observational study assessing rivaroxaban use in a broad patient population with NVAF in 17 countries across EEMEA and Latin America.

XANTUS is the first large, international, prospective study describing the use of rivaroxaban for stroke prevention in a broad NVAF patient ...

According to investigators, the findings confirm clinical trial data and demonstrate that oral anticoagulation with rivaroxaban is safe and ...

XANTUS investigated the safety and efficacy of the Factor Xa inhibitor ... non-valvular atrial fibrillation (NVAF) based on clinical trial ...

The researchers noted that the XANTUS program offers a unique source ... and Israel (XANTUS trial), the Asia-Pacific region (XANAP trial), ...

Patients with Atrial Fibrillation in Asia) and XANTUS-EL (Xarelto® for ... results from previous phase III trials, including ROCKET AF (Rivaroxaban ...

XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients...

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.

17.07.2014 · XANTUS (Xarelto (®) for Prevention of Stroke in Patients with Atrial Fibrillation) is a prospective, international, observational, postauthorization, noninterventional study designed to collect safety and efficacy data on the use of rivaroxaban for stroke prevention in AF in routine clinical practice.

Sep 01, 2015 · Font Size A A A Atrial fibrillation (AFib) patients treated with rivaroxaban for stroke prevention have low rates of bleeding and stroke, according to data from the XANTUS study presented Sept. 1 during ESC Congress 2015 in London and simultaneously published in European Heart Journal.

Jul 17, 2014 · XANTUS (Xarelto (®) for Prevention of Stroke in Patients with Atrial Fibrillation) is a prospective, international, observational, postauthorization, noninterventional study designed to collect safety and efficacy data on the use of rivaroxaban for stroke prevention in AF in routine clinical practice.

Aims: Based on Phase III data, non-vitamin K antagonist oral anticoagulants are recommended for stroke prevention in patients with atrial fibrillation.